Opinion on Pharmaceuticals and Healthcare in Israel

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Oxford GlycoSciences/Teva: identifying Israeli opportunities

The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.

Published By Datamonitor
21 Nov 2001
CommentWire
CommentWire

Peptor: investigating additional indications in diabetes

DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.

Published By Datamonitor
15 Jan 2002
CommentWire
CommentWire

Generic drugs: Ivax purchase puts Teva back on top

Teva has agreed to acquire rival generics maker Ivax for $7.4 billion. If the deal goes through, Teva will become the dominant force in the generics market again, pushing Novartis' Sandoz into second place. As the gap between these top two players and the rest of the field opens up, smaller companies may struggle to keep pace and could end up being takeover targets themselves.

Published By Datamonitor
26 Jul 2005
CommentWire
CommentWire

Teva: Copaxone on the up

Teva's biggest selling drug Copaxone has shown increased efficacy in multiple sclerosis in a high-dose phase II trial. This points to the possibility of a revival in Copaxone use, and increased competition for Biogen Idec and Elan's Tysabri if and when it is re-launched.

Published By Datamonitor
07 Apr 2006
CommentWire
CommentWire

Teva: FDA green light good news for Azilect

Teva Pharmaceutical has received FDA approval for Azilect as a treatment for Parkinson's disease, both as initial monotherapy in early Parkinson's patients and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease. While this is good news for Teva's second proprietary drug, its true potential may only be realized once long-term neuroprotection trials are completed.

Published By Datamonitor
19 May 2006
CommentWire
CommentWire

Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial

CF101, an orally-available TNF-alpha antagonist, has shown promising results in a Phase IIa study for the treatment of moderate to severe psoriasis. With current therapies focused on topical agents and biologics, this interesting oral compound has potential benefits for an unmet need in the treatment of psoriasis.

Published By Datamonitor
09 Sep 2009
CommentWire
CommentWire

Cubist Pharmaceuticals/Teva: US generics deal agreed for Cubicin

Cubist Pharmaceuticals has granted Teva a non-exclusive license to launch a generic version of its antibiotic Cubicin in the US. The move brings the dispute - which had been running since 2009 - to a close, and eliminates the risk of Cubist losing Cubicin sales in the event of Teva winning the patent litigation.

Published By Datamonitor
08 Apr 2011
CommentWire
CommentWire

Teva and Active Biotech: Phase III results cast shadow over MS approval

Teva's laquinimod has failed to meet its primary Phase III endpoint of reducing annualized relapse rate. This is a blow for Teva and development partner Active Biotech, as the drug was on track to become the next oral disease-modifying therapy available for multiple sclerosis (MS). However, hope remains for the drug's potential in Crohn's disease and lupus, for which Phase II trials are ongoing.

Published By Datamonitor
02 Aug 2011

« | 1 | » »|

No help is available.